Free Trial

Propanc Biopharma (PPCB) 10K Form and Latest SEC Filings 2026

Propanc Biopharma logo
$0.10 0.00 (-0.29%)
As of 04:00 PM Eastern

Latest Propanc Biopharma SEC Filings & Recent Activity

Propanc Biopharma (OTCMKTS:PPCB) has submitted 184+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form EFFECT submitted on April 20, 2026.

10-Q
Propanc Biopharma Files Quarterly Report on Feb. 17, 2026

The 10-Q contains Propanc Biopharma's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Propanc Biopharma SEC Filing History

Browse Propanc Biopharma's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/20/2026 11:15 PM
Propanc Biopharma (1517681) Filer
Form EFFECT
04/10/2026 4:29 PM
Propanc Biopharma (1517681) Filer
Form S-1
Registration statement under Securities Act of 1933  
03/31/2026 5:12 AM
Propanc Biopharma (1517681) Filer
Form DEF 14C
03/19/2026 4:30 PM
Propanc Biopharma (1517681) Filer
Form PRE 14A
03/06/2026 4:22 PM
Propanc Biopharma (1517681) Filer
Form 424B3
02/26/2026 4:19 PM
Propanc Biopharma (1517681) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/24/2026 11:15 PM
Propanc Biopharma (1517681) Filer
Form EFFECT
02/19/2026 4:28 PM
Propanc Biopharma (1517681) Filer
Form S-1/A
02/17/2026 1:54 PM
Propanc Biopharma (1517681) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
02/02/2026 4:29 PM
Propanc Biopharma (1517681) Filer
Form S-1
Registration statement under Securities Act of 1933  
01/29/2026 8:33 PM
Propanc Biopharma (1517681) Filer
Form 424B3
01/11/2026 11:15 PM
Propanc Biopharma (1517681) Filer
Form EFFECT
01/07/2026 4:00 PM
Propanc Biopharma (1517681) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/29/2025 7:05 PM
Propanc Biopharma (1517681) Filer
Form S-1
Registration statement under Securities Act of 1933  
12/29/2025 4:13 PM
Propanc Biopharma (1517681) Filer
Form DEF 14C
12/10/2025 4:24 PM
Propanc Biopharma (1517681) Filer
Form PRE 14C
11/14/2025 3:05 PM
Ionic Ventures, LLC (1769419) Filed by
Propanc Biopharma (1517681) Subject
Form SCHEDULE 13G/A
11/10/2025 4:22 PM
Propanc Biopharma (1517681) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/14/2025 4:25 PM
Propanc Biopharma (1517681) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/29/2025 4:29 PM
Propanc Biopharma (1517681) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
08/19/2025 4:24 PM
Propanc Biopharma (1517681) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/13/2025 11:15 PM
Propanc Biopharma (1517681) Filer
Form EFFECT
08/13/2025 4:13 PM
Propanc Biopharma (1517681) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/13/2025 4:14 PM
Propanc Biopharma (1517681) Filer
Form 8-A12B
07/30/2025 3:44 PM
Propanc Biopharma (1517681) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/28/2025 4:12 PM
Propanc Biopharma (1517681) Filer
Form S-1/A
06/18/2025 4:24 PM
Propanc Biopharma (1517681) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/02/2025 4:29 PM
Propanc Biopharma (1517681) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/30/2025 2:39 PM
Propanc Biopharma (1517681) Filer
Form S-1/A
05/07/2025 8:56 PM
Propanc Biopharma (1517681) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Propanc Biopharma SEC Filings - Frequently Asked Questions

Propanc Biopharma (PPCB) has submitted 184+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Propanc Biopharma's fiscal year ends on June 30. The company typically files its 10-K annual report by the end of August, covering the prior fiscal year's financial results.

The most recent filing was a Form EFFECT submitted on April 20, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (OTCMKTS:PPCB) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners